Kroeger, Nicolaus and Holler, Ernst and Kobbe, Guido and Bornhaeuser, Martin and Schwerdtfeger, Rainer and Baurmann, Herrad and Nagler, Arnon and Bethge, Wolfgang and Stelljes, Matthias and Uharek, Lutz and Wandt, Hannes and Burchert, Andreas and Corradini, Paolo and Schubert, Joerg and Kaufmann, Martin and Dreger, Peter and Wulf, Gerald G. and Einsele, Hermann and Zabelina, Tatjana and Kvasnicka, Hans Michael and Thiele, Juergen and Brand, Ronald and Zander, Axel R. and Niederwieser, Dietger and de Witte, Theo M. (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. BLOOD, 114 (26). pp. 5264-5270. ISSN 0006-4971,
Full text not available from this repository. (Request a copy)Abstract
From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70). All but 2 patients (2%) showed leukocyte and platelet engraftment after a median of 18 and 22 days, respectively. Acute graft-versus-host disease grade 2 to 4 occurred in 27% and chronic graft-versus-host disease in 43% of the patients. Cumulative incidence of nonrelapse mortality at 1 year was 16% (95% confidence interval, 9%-23%) and significantly lower for patients with a completely matched donor (12% vs 38%; P = .003). The cumulative incidence of relapse at 3 years was 22% (95% confidence interval, 13%-31%) and was influenced by Lille risk profile (low, 14%; inter-mediate, 22%; and high, 34%; P = .02). The estimated 5-year event-free and overall survival was 51% and 67%, respectively. In a multivariate analysis, age older than 55 years (hazard ratio = 2.70; P = .02) and human leukocyte antigen-mismatched donor (hazard ratio = 3.04; P = .006) remained significant factors for survival. The study was registered at www.clinicaltrials.gov as # NCT 00599547. (Blood. 2009; 114: 5264-5270)
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | AGNOGENIC MYELOID METAPLASIA; DONOR-LYMPHOCYTE INFUSION; IDIOPATHIC MYELOFIBROSIS; ESSENTIAL THROMBOCYTHEMIA; MYELOPROLIFERATIVE DISORDERS; PROGNOSTIC-FACTORS; GRUPPO-ITALIANO; MIDOLLO-OSSEO; GRAFT; MUTATION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Aug 2020 08:45 |
| Last Modified: | 27 Aug 2020 08:45 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27969 |
Actions (login required)
 |
View Item |
